Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 35Lymphoma, Large B-Cell, Diffuse 22Sarcoma 19Lymphoma 19Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Non-Hodgkin 9Hodgkin Disease 9Multiple Myeloma 8Leukemia 8Neuroblastoma 6Liver Neoplasms 6Lymphoma, Follicular 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Triple Negative Breast Neoplasms 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Liposarcoma 3Leiomyosarcoma 3Chondrosarcoma 3Burkitt Lymphoma 3Wilms Tumor 2Rhabdomyosarcoma 2

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Cyclophosphamide 2pembrolizumab 1Vincristine 1Prednisone 1Interleukin-21 1Etoposide 1Doxorubicin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Experimental × Doxorubicin × Clear all
NCT03617432 2018-09-04

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Peking University

Phase 2 Unknown
114 enrolled

Neoplasms, Experimental

Data powered by HemOnc (CC BY 4.0) Colophon âš¡